Selected Publications
Click HERE for my PubMed
Cervia LD, Shibue T, Borah AA, Gaeta B, He L, Leung L, Li N, Moyer SM, Shim BH, Dumont N, Gonzalez A, Bick NR, Kazachkova M, Dempster JM, Krill-Burger JM, Piccioni F, Udeshi ND, Olive ME, Carr SA, Root DE, McFarland JM, Vazquez F, Hahn WC. A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer Discov. 2023 Mar 1;13(3):766-795. doi: 10.1158/2159-8290.CD-22-1230. PMID: 36576405; PMCID: PMC9975667.
Schröfelbauer B, Kimes PK, Hauke P, Reid CE, Shao K, Hill SJ, Irizarry R, Hahn WC. Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2206751120. doi: 10.1073/pnas.2206751120. Epub 2022 Dec 27. PMID: 36574667; PMCID: PMC9910589.
Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC. Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023 Feb 15;83(4):613-625. doi: 10.1158/0008-5472.CAN-22-2245. PMID: 36548402; PMCID: PMC9929516.
So J, Mabe NW, Englinger B, Chow KH, Moyer SM, Yerrum S, Trissal MC, Marques JG, Kwon JJ, Shim B, Pal S, Panditharatna E, Quinn T, Schaefer DA, Jeong D, Mayhew DL, Hwang J, Beroukhim R, Ligon KL, Stegmaier K, Filbin MG, Hahn WC. VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 Oct 10;7(19):e158755. doi: 10.1172/jci.insight.158755. PMID: 36040810; PMCID: PMC9675470.
Pan J, Kwon JJ, Talamas JA, Borah AA, Vazquez F, Boehm JS, Tsherniak A, Zitnik M, McFarland JM, Hahn WC. Sparse dictionary learning recovers pleiotropy from human cell fitness screens. Cell Syst. 2022 Apr 20;13(4):286-303.e10. doi: 10.1016/j.cels.2021.12.005. Epub 2022 Jan 31. PMID: 35085500; PMCID: PMC9035054.
Kim M, Ly SH, Xie Y, Duronio GN, Ford-Roshon D, Hwang JH, Sulahian R, Rennhack JP, So J, Gjoerup O, Talamas JA, Grandclaudon M, Long HW, Doench JG, Sethi NS, Giannakis M, Hahn WC. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Dev Cell. 2022 Jan 24;57(2):212-227.e8. doi: 10.1016/j.devcel.2021.12.006. Epub 2022 Jan 5. PMID: 34990589; PMCID: PMC8827663.
Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, So J, Kregel S, Van Allen EM, Drake JM, Freedman ML, Hahn WC. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. Elife. 2022 May 12;11:e73223. doi: 10.7554/eLife.73223. PMID: 35550030; PMCID: PMC9135408.
Dai C, Rennhack JP, Arnoff TE, Thaker M, Younger ST, Doench JG, Huang AY, Yang A, Aguirre AJ, Wang B, Mun E, O'Connell JT, Huang Y, Labella K, Talamas JA, Li J, Ilic N, Hwang J, Hong AL, Giacomelli AO, Gjoerup O, Root DE, Hahn WC. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Rep. 2021 Jul 27;36(4):109443. doi: 10.1016/j.celrep.2021.109443. PMID: 34320363; PMCID: PMC8350598.
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, Ly SH, Han C, Dai C, Pakula H, Sheahan A, Piccioni F, Gjoerup O, Loda M, Sowalsky AG, Ellis L, Long H, Root DE, Kelly K, Van Allen EM, Freedman ML, Choudhury AD, Hahn WC (2019). CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 Nov 19;29(8):2355-2370.e6
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ (2019). Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019 Oct 1;29(1):118-134.e8.
Hahn, WC. (2019). A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019 Jun 20;380(25):2475-2477.
Price C, Gill S, Ho ZV, Davidson SM, Merkel E, McFarland JM, Leung L, Tang A, Kost-Alimova M, Tsherniak A, Jonas O, Vazquez F, and Hahn WC. (2019). Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019 May 15;79(10):2564-2579.
Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, Ward A, McSteen B, Labella KM, Keskula P, Tracy A, Connor C, Clinton CM, Church AJ, Crompton BD, Janeway KA, Van Hare B, Sandak D, Gjoerup O, Bandopadhayay P, Clemons PA, Schreiber SL, Root DE, Gokhale PC, Chi SN, Mullen EA, Roberts CW, Kadoch C, Beroukhim R, Ligon KL, Boehm JS, and Hahn WC. (2019). Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 Mar 12;8.
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, and Hahn WC. (2019). MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 Jun;17(6):1294-130.
Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, and Roberts CWM. (2019). MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 May 1;79(9):2404-2414.
Aguirre, A.J., Nowak, J.A., Camarda, N.D., Moffitt, R.A., Ghazani, A.A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L.K., Ragon, D., Welch, M.W., Reilly, E., McCabe, D., Marini, L., Anderka, K., Helvie, K., Oliver, N., Babic, A., Da Silva, A., Nadres, B., Van Seventer, E.E., Shahzade, H.A., St Pierre, J.P., Burke, K.P., Clancy, T., Cleary, J.M., Doyle, L.A., Jajoo, K., McCleary, N.J., Meyerhardt, J.A., Murphy, J.E., Ng, K., Patel, A.K., Perez, K., Rosenthal, M.H., Rubinson, D.A., Ryou, M., Shapiro, G.I., Sicinska, E., Silverman, S.G., Nagy, R.J., Lanman, R.B., Knoerzer, D., Welsch, D.J., Yurgelun, M.B., Fuchs, C.S., Garraway, L.A., Getz, G., Hornick, J.L., Johnson, B.E., Kulke, M.H., Mayer, R.J., Miller, J.W., Shyn, P.B., Tuveson, D.A., Wagle, N., Yeh, J.J., Hahn, W.C., Corcoran, R.B., Carter, S.L., and Wolpin, B.M. (2018). Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer discovery 8, 1096-1111.
Durbin, A.D., Zimmerman, M.W., Dharia, N.V., Abraham, B.J., Iniguez, A.B., Weichert-Leahey, N., He, S., Krill-Burger, J.M., Root, D.E., Vazquez, F., Tsherniak, A., Hahn, W.C., Golub, T.R., Young, R.A., Look, A.T., and Stegmaier, K. (2018). Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature genetics 50, 1240-1246.
Giacomelli, A.O., Yang, X., Lintner, R.E., McFarland, J.M., Duby, M., Kim, J., Howard, T.P., Takeda, D.Y., Ly, S.H., Kim, E., Gannon, H.S., Hurhula, B., Sharpe, T., Goodale, A., Fritchman, B., Steelman, S., Vazquez, F., Tsherniak, A., Aguirre, A.J., Doench, J.G., Piccioni, F., Roberts, C.W.M., Meyerson, M., Getz, G., Johannessen, C.M., Root, D.E., and Hahn, W.C. (2018). Mutational processes shape the landscape of TP53 mutations in human cancer. Nature genetics 50, 1381-1387.
Choudhury, A.D., Werner, L., Francini, E., Wei, X.X., Ha, G., Freeman, S.S., Rhoades, J., Reed, S.C., Gydush, G., Rotem, D., Lo, C., Taplin, M.E., Harshman, L.C., Zhang, Z., O'Connor, E.P., Stover, D.G., Parsons, H.A., Getz, G., Meyerson, M., Love, J.C., Hahn, W.C., and Adalsteinsson, V.A. (2018). Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3.
McFarland, J.M., Ho, Z.V., Kugener, G., Dempster, J.M., Montgomery, P.G., Bryan, J.G., Krill-Burger, J.M., Green, T.M., Vazquez, F., Boehm, J.S., Golub, T.R., Hahn, W.C., Root, D.E., and Tsherniak, A. (2018). Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nature communications 9, 4610.
Lo, J.H., Hao, L., Muzumdar, M.D., Raghavan, S., Kwon, E.J., Pulver, E.M., Hsu, F., Aguirre, A.J., Wolpin, B.M., Fuchs, C.S., Hahn, W.C., Jacks, T., and Bhatia, S.N. (2018). iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Molecular cancer therapeutics 17, 2377-2388.
Pan, J., Meyers, R.M., Michel, B.C., Mashtalir, N., Sizemore, A.E., Wells, J.N., Cassel, S.H., Vazquez, F., Weir, B.A., Hahn, W.C., Marsh, J.A., Tsherniak, A., and Kadoch, C. (2018). Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst 6, 555-568 e557.
Ng, S.Y., Yoshida, N., Christie, A.L., Ghandi, M., Dharia, N.V., Dempster, J., Murakami, M., Shigemori, K., Morrow, S.N., Van Scoyk, A., Cordero, N.A., Stevenson, K.E., Puligandla, M., Haas, B., Lo, C., Meyers, R., Gao, G., Cherniack, A., Louissaint, A., Jr., Nardi, V., Thorner, A.R., Long, H., Qiu, X., Morgan, E.A., Dorfman, D.M., Fiore, D., Jang, J., Epstein, A.L., Dogan, A., Zhang, Y., Horwitz, S.M., Jacobsen, E.D., Santiago, S., Ren, J.G., Guerlavais, V., Annis, D.A., Aivado, M., Saleh, M.N., Mehta, A., Tsherniak, A., Root, D., Vazquez, F., Hahn, W.C., Inghirami, G., Aster, J.C., Weinstock, D.M., and Koch, R. (2018). Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature communications 9, 2024.
Qian, Z.R., Rubinson, D.A., Nowak, J.A., Morales-Oyarvide, V., Dunne, R.F., Kozak, M.M., Welch, M.W., Brais, L.K., Da Silva, A., Li, T., Li, W., Masuda, A., Yang, J., Shi, Y., Gu, M., Masugi, Y., Bui, J., Zellers, C.L., Yuan, C., Babic, A., Khalaf, N., Aguirre, A., Ng, K., Miksad, R.A., Bullock, A.J., Chang, D.T., Tseng, J.F., Clancy, T.E., Linehan, D.C., Findeis-Hosey, J.J., Doyle, L.A., Thorner, A.R., Ducar, M., Wollison, B., Laing, A., Hahn, W.C., Meyerson, M., Fuchs, C.S., Ogino, S., Hornick, J.L., Hezel, A.F., Koong, A.C., and Wolpin, B.M. (2018). Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA oncology 4, e173420.
Li, J., Choi, P.S., Chaffer, C.L., Labella, K., Hwang, J.H., Giacomelli, A.O., Kim, J.W., Ilic, N., Doench, J.G., Ly, S.H., Dai, C., Hagel, K., Hong, A.L., Gjoerup, O., Goel, S., Ge, J.Y., Root, D.E., Zhao, J.J., Brooks, A.N., Weinberg, R.A., and Hahn, W.C. (2018). An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. eLife 7.
Ng, K., Hendifar, A., Starodub, A., Chaves, J., Yang, Y., Koh, B., Barbie, D., Hahn, W.C., and Fuchs, C.S. (2018). Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational new drugs.
Takeda, D.Y., Spisak, S., Seo, J.H., Bell, C., O'Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szallasi, Z., Stillman, D.R., Cejas, P., Qiu, X., Long, H.W., Tisza, V., Nuzzo, P.V., Rohanizadegan, M., Pomerantz, M.M., Hahn, W.C., and Freedman, M.L. (2018). A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell 174, 422-432 e413.
Yurgelun, M.B., Chittenden, A.B., Morales-Oyarvide, V., Rubinson, D.A., Dunne, R.F., Kozak, M.M., Qian, Z.R., Welch, M.W., Brais, L.K., Da Silva, A., Bui, J.L., Yuan, C., Li, T., Li, W., Masuda, A., Gu, M., Bullock, A.J., Chang, D.T., Clancy, T.E., Linehan, D.C., Findeis-Hosey, J.J., Doyle, L.A., Thorner, A.R., Ducar, M.D., Wollison, B.M., Khalaf, N., Perez, K., Syngal, S., Aguirre, A.J., Hahn, W.C., Meyerson, M.L., Fuchs, C.S., Ogino, S., Hornick, J.L., Hezel, A.F., Koong, A.C., Nowak, J.A., and Wolpin, B.M. (2018). Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med.
Viswanathan, S.R., Nogueira, M.F., Buss, C.G., Krill-Burger, J.M., Wawer, M.J., Malolepsza, E., Berger, A.C., Choi, P.S., Shih, J., Taylor, A.M., Tanenbaum, B., Pedamallu, C.S., Cherniack, A.D., Tamayo, P., Strathdee, C.A., Lage, K., Carr, S.A., Schenone, M., Bhatia, S.N., Vazquez, F., Tsherniak, A., Hahn, W.C., and Meyerson, M. (2018). Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nature genetics 50, 937-943.
Chen, L., Alexe, G., Dharia, N.V., Ross, L., Iniguez, A.B., Conway, A.S., Wang, E.J., Veschi, V., Lam, N., Qi, J., Gustafson, W.C., Nasholm, N., Vazquez, F., Weir, B.A., Cowley, G.S., Ali, L.D., Pantel, S., Jiang, G., Harrington, W.F., Lee, Y., Goodale, A., Lubonja, R., Krill-Burger, J.M., Meyers, R.M., Tsherniak, A., Root, D.E., Bradner, J.E., Golub, T.R., Roberts, C.W., Hahn, W.C., Weiss, W.A., Thiele, C.J., and Stegmaier, K. (2018). CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. The Journal of clinical investigation 128, 446-462.
Horn, H., Lawrence, M.S., Chouinard, C.R., Shrestha, Y., Hu, J.X., Worstell, E., Shea, E., Ilic, N., Kim, E., Kamburov, A., Kashani, A., Hahn, W.C., Campbell, J.D., Boehm, J.S., Getz, G., and Lage, K. (2018). NetSig: network-based discovery from cancer genomes. Nature methods 15, 61-66.
Zhang, X., Choi, P.S., Francis, J.M., Gao, G.F., Campbell, J.D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., Tsherniak, A., Taylor, A.M., Zhou, J., Wu, Z., Berger, A.C., Giannakis, M., Hahn, W.C., Cherniack, A.D., and Meyerson, M. (2018). Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer discovery 8, 108-125.
Sandoval, G.J., Pulice, J.L., Pakula, H., Schenone, M., Takeda, D.Y., Pop, M., Boulay, G., Williamson, K.E., McBride, M.J., Pan, J., St Pierre, R., Hartman, E., Garraway, L.A., Carr, S.A., Rivera, M.N., Li, Z., Ronco, L., Hahn, W.C., and Kadoch, C. (2018). Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Molecular cell 71, 554-566 e557.
Aguirre, A.J., and Hahn, W.C. (2018). Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harbor perspectives in medicine 8.
Meyers, R.M., Bryan, J.G., McFarland, J.M., Weir, B.A., Sizemore, A.E., Xu, H., Dharia, N.V., Montgomery, P.G., Cowley, G.S., Pantel, S., Goodale, A., Lee, Y., Ali, L.D., Jiang, G., Lubonja, R., Harrington, W.F., Strickland, M., Wu, T., Hawes, D.C., Zhivich, V.A., Wyatt, M.R., Kalani, Z., Chang, J.J., Okamoto, M., Stegmaier, K., Golub, T.R., Boehm, J.S., Vazquez, F., Root, D.E., Hahn, W.C., and Tsherniak, A. (2017). Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nature genetics.
Gonen, M., Weir, B.A., Cowley, G.S., Vazquez, F., Guan, Y., Jaiswal, A., Karasuyama, M., Uzunangelov, V., Wang, T., Tsherniak, A., Howell, S., Marbach, D., Hoff, B., Norman, T.C., Airola, A., Bivol, A., Bunte, K., Carlin, D., Chopra, S., Deran, A., Ellrott, K., Gopalacharyulu, P., Graim, K., Kaski, S., Khan, S.A., Newton, Y., Ng, S., Pahikkala, T., Paull, E., Sokolov, A., Tang, H., Tang, J., Wennerberg, K., Xie, Y., Zhan, X., Zhu, F., Broad, D.C., Aittokallio, T., Mamitsuka, H., Stuart, J.M., Boehm, J.S., Root, D.E., Xiao, G., Stolovitzky, G., Hahn, W.C., and Margolin, A.A. (2017). A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst 5, 485-497 e483.
Zwang, Y., Jonas, O., Chen, C., Rinne, M.L., Doench, J.G., Piccioni, F., Tan, L., Huang, H.T., Wang, J., Ham, Y.J., et al. (2017). Synergistic interactions with PI3K inhibition that induce apoptosis. Elife 6.
Rosenbluh, J., Xu, H., Harrington, W., Gill, S., Wang, X., Vazquez, F., Root, D.E., Herniate, A., and Hahn, W.C. (2017). Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun 8, 15403.
Sandoval, G.J., and Hahn, W.C. (2017). Going beyond genetics to discover cancer targets. Genome Biol 18, 95.
Hsu, J.H., Hubbell-Engler, B., Adelmant, G., Huang, J., Joyce, C.E., Vazquez, F., Weir, B.A., Montgomery, P., Tsherniak, A., Giacomelli, A.O., et al. (2017). PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res.
Sun, Y., Alberta, J.A., Pilarz, C., Calligaris, D., Chadwick, E.J., Ramkissoon, S.H., Ramkissoon, L.A., Garcia, V.M., Mazzola, E., Goumnerova, L., et al. (2017). A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol 19, 774-785.
Tsherniak, A., Vazquez, F., Montgomery, P.G., Weir, B.A., Kryukov, G., Cowley, G.S., Gill, S., Harrington, W.F., Pantel, S., Krill-Burger, J.M., et al. (2017). Defining a Cancer Dependency Map. Cell 170, 564-576 e516.
Viswanathan, V.S., Ryan, M.J., Dhruv, H.D., Gill, S., Eichhoff, O.M., Seashore-Ludlow, B., Kaffenberger, S.D., Eaton, J.K., Shimada, K., Aguirre, A.J., et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453-457.
Li, H., Mar, B.G., Zhang, H., Puram, R.V., Vazquez, F., Weir, B.A., Hahn, W.C., Ebert, B., and Pellman, D. (2017). The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129, 497-508.
Ni, J., Xie, S., Ramkissoon, S.H., Luu, V., Sun, Y., Bandopadhayay, P., Beroukhim, R., Roberts, T.M., Stiles, C.D., Segal, R.A., et al. (2017). Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19, 22-30.
Paolella, B.R., Gibson, W.J., Urbanski, L.M., Alberta, J.A., Zack, T.I., Bandopadhayay, P., Nichols, C.A., Agarwalla, P.K., Brown, M.S., Lamothe, R., et al. (2017). Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife 6.
Wang, B., Krall, E.B., Aguirre, A.J., Kim, M., Widlund, H.R., Doshi, M.B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G.S., et al. (2017). ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep 18, 1543-1557.
Choudhury, A.D., Schinzel, A.C., Cotter, M.B., Lis, R.T., Labella, K., Lock, Y.J., Izzo, F., Guney, I., Bowden, M., Li, Y.Y., et al. (2017). Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res 77, 753-765.
Krall, E.B., Wang, B., Munoz, D.M., Ilic, N., Raghavan, S., Niederst, M.J., Yu, K., Ruddy, D.A., Aguirre, A.J., Kim, J.W., et al. (2017). KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife 6.
Day, T.A., Layer, J.V., Cleary, J.P., Guha, S., Stevenson, K.E., Tivey, T., Kim, S., Schinzel, A.C., Izzo, F., Doench, J., et al. (2017). PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun 8, 15110.
Ilic, N., Birsoy, K., Aguirre, A.J., Kory, N., Pacold, M.E., Singh, S., Moody, S.E., DeAngelo, J.D., Spardy, N.A., Freinkman, E., et al. (2017). PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A 114, E3434-E3443.
Rosenbluh, J., Mercer, J., Shrestha, Y., Oliver, R., Tamayo, P., Doench, J.G., Tirosh, I., Piccioni, F., Hartenian, E., Horn, H., et al. (2016). Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers. Cell Syst 3, 302-316 e304.
Sholl, L.M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A.M., Kuo, F.C., Garcia, E.P., Jia, Y., Davineni, P., Abo, R.P., et al. (2016). Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062.
Howard, T.P., Vazquez, F., Tsherniak, A., Hong, A.L., Rinne, M., Aguirre, A.J., Boehm, J.S., and Hahn, W.C. (2016). Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol 81, 237-246.
Kim, J. W., Botvinnik, O. B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M. E., Hammerman, P. S., DiCara, D., Konieczkowski, D. J., et al. (2016a). Characterizing genomic alterations in cancer by complementary functional associations. Nature biotechnology 34, 539-546.
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016). MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214-1218.
Bellmunt, J., Zhou, C. W., Mullane, S. A., Werner, L., Taplin, M. E., Fay, A. P., Choueiri, T. K., Orsola, A., Takeda, D. Y., Hahn, W. C., et al. (2016). Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British journal of cancer 115, 12-19.
Aguirre, A. J., Meyers, R. M., Weir, B. A., Vazquez, F., Zhang, C. Z., Ben-David, U., Cook, A., Ha, G., Harrington, W. F., Doshi, M. B., et al. (2016). Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer discovery.
Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. (2016b). Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer discovery 6, 714-726.
Gannon, H. S., Kaplan, N., Tsherniak, A., Vazquez, F., Weir, B. A., Hahn, W. C., and Meyerson, M. (2016). Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Molecular cancer research : MCR 14, 207-215.
Hong, A. L., Tseng, Y. Y., Cowley, G. S., Jonas, O., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016). Integrated genetic and pharmacologic interrogation of rare cancers. Nature communications 7, 11987.
Luo, L. Y., and Hahn, W. C. (2015). Oncogenic Signaling Adaptor Proteins. Journal of genetics and genomics = Yi chuan xue bao 42, 521-529.
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015). AACR Cancer Progress Report 2015. Clinical cancer research : an official journal of the American Association for Cancer Research 21, S1-128.
Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015). The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nature genetics 47, 1346-1351.
Brastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015). Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer discovery 5, 1164-1177.
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015). A functional landscape of resistance to ALK inhibition in lung cancer. Cancer cell 27, 397-408.
White, E. A., Kramer, R. E., Hwang, J. H., Pores Fernando, A. T., Naetar, N., Hahn, W. C., Roberts, T. M., Schaffhausen, B. S., Livingston, D. M., and Howley, P. M. (2015). Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. Journal of virology 89, 2857-2865.
Luo, L. Y., Kim, E., Cheung, H. W., Weir, B. A., Dunn, G. P., Shen, R. R., and Hahn, W. C. (2015). The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular cancer research : MCR 13, 502-509.
Hwang, J. H., Pores Fernando, A. T., Faure, N., Andrabi, S., Adelmant, G., Hahn, W. C., Marto, J. A., Schaffhausen, B. S., and Roberts, T. M. (2015). Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. Journal of virology 89, 6971.
Shen, R. R., Zhou, A. Y., Kim, E., O'Connell, J. T., Hagerstrand, D., Beroukhim, R., and Hahn, W. C. (2015). TRAF2 is an NF-kappaB-activating oncogene in epithelial cancers. Oncogene 34, 209-216.
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L. C., Kung, A. L., et al. (2015). An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America 112, 232-237.
Abo, R. P., Ducar, M., Garcia, E. P., Thorner, A. R., Rojas-Rudilla, V., Lin, L., Sholl, L. M., Hahn, W. C., Meyerson, M., Lindeman, N. I., et al. (2015). BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic acids research 43, e19.
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015). SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nature medicine 21, 1491-1496.
Shankar, G. M., Francis, J. M., Rinne, M. L., Ramkissoon, S. H., Huang, F. W., Venteicher, A. S., Akama-Garren, E. H., Kang, Y. J., Lelic, N., Kim, J. C., et al. (2015). Rapid Intraoperative Molecular Characterization of Glioma. JAMA oncology 1, 662-667.
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., and Hahn, W. C. (2015). PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 34, 2061-2071.
Chen, C. W., Koche, R. P., Sinha, A. U., Deshpande, A. J., Zhu, N., Eng, R., Doench, J. G., Xu, H., Chu, S. H., Qi, J., et al. (2015). DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature medicine 21, 335-343.
Hettmer, S., Schinzel, A. C., Tchessalova, D., Schneider, M., Parker, C. L., Bronson, R. T., Richards, N. G., Hahn, W. C., and Wagers, A. J. (2015). Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife 4.
Huang, F. W., Bielski, C. M., Rinne, M. L., Hahn, W. C., Sellers, W. R., Stegmeier, F., Garraway, L. A., and Kryukov, G. V. (2015). TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4, e176.
Sevenich, L., Bowman, R. L., Mason, S. D., Quail, D. F., Rapaport, F., Elie, B. T., Brogi, E., Brastianos, P. K., Hahn, W. C., Holsinger, L. J., et al. (2014). Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nature cell biology 16, 876-888.
Hwang, J. H., Pores Fernando, A. T., Faure, N., Andrabi, S., Adelmant, G., Hahn, W. C., Marto, J. A., Schaffhausen, B. S., and Roberts, T. M. (2014). Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. Journal of virology 88, 12055-12064.
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., et al. (2014). Prospective enterprise-level molecular genotyping of a cohort of cancer patients. The Journal of molecular diagnostics : JMD 16, 660-672.
Lohr, J. G., Adalsteinsson, V. A., Cibulskis, K., Choudhury, A. D., Rosenberg, M., Cruz-Gordillo, P., Francis, J. M., Zhang, C. Z., Shalek, A. K., Satija, R., et al. (2014). Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature biotechnology 32, 479-484.
Wilson, B. G., Helming, K. C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W. C., and Roberts, C. W. (2014). Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Molecular and cellular biology 34, 1136-1144.
Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014). ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature medicine 20, 251-254.
Naetar, N., Soundarapandian, V., Litovchick, L., Goguen, K. L., Sablina, A. A., Bowman-Colin, C., Sicinski, P., Hahn, W. C., DeCaprio, J. A., and Livingston, D. M. (2014). PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Molecular cell 54, 932-945.
Lane, A. A., Chapuy, B., Lin, C. Y., Tivey, T., Li, H., Townsend, E. C., van Bodegom, D., Day, T. A., Wu, S. C., Liu, H., et al. (2014). Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature genetics 46, 618-623.
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014). KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184.
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Kramer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124, 13-23.
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014). A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer discovery 4, 816-827.
Chudnovsky, Y., Kim, D., Zheng, S., Whyte, W. A., Bansal, M., Bray, M. A., Gopal, S., Theisen, M. A., Bilodeau, S., Thiru, P., et al. (2014). ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell reports 6, 313-324.
Dunn, G. P., Cheung, H. W., Agarwalla, P. K., Thomas, S., Zektser, Y., Karst, A. M., Boehm, J. S., Weir, B. A., Berlin, A. M., Zou, L., et al. (2014). In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America 111, 1102-1107.
Rosenbluh, J., Wang, X., and Hahn, W. C. (2014). Genomic insights into WNT/beta-catenin signaling. Trends in pharmacological sciences 35, 103-109.
Brastianos, P. K., Taylor-Weiner, A., Manley, P. E., Jones, R. T., Dias-Santagata, D., Thorner, A. R., Lawrence, M. S., Rodriguez, F. J., Bernardo, L. A., Schubert, L., et al. (2014). Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature genetics 46, 161-165.
Sulahian, R., Casey, F., Shen, J., Qian, Z. R., Shin, H., Ogino, S., Weir, B. A., Vazquez, F., Liu, X. S., Hahn, W. C., et al. (2014). An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene 33, 5637-5648.
Giannakis, M., Hodis, E., Jasmine Mu, X., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., Lawrence, M. S., Qian, Z. R., Nishihara, R., et al. (2014). RNF43 is frequently mutated in colorectal and endometrial cancers. Nature genetics 46, 1264-1266.
Riester, M., Werner, L., Bellmunt, J., Selvarajah, S., Guancial, E. A., Weir, B. A., Stack, E. C., Park, R. S., O'Brien, R., Schutz, F. A., et al. (2014). Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 20, 1873-1883.
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014). Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer discovery 4, 452-465.
Hagerstrand, D., Tong, A., Schumacher, S. E., Ilic, N., Shen, R. R., Cheung, H. W., Vazquez, F., Shrestha, Y., Kim, S. Y., Giacomelli, A. O., et al. (2013). Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer discovery 3, 1044-1057.
Etemadmoghadam, D., Au-Yeung, G., Wall, M., Mitchell, C., Kansara, M., Loehrer, E., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013). Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 19, 5960-5971.
Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., MacConaill, L. E., Shoni, M., Wagle, N., Jones, R. T., et al. (2013). Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783.
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., Schumacher, S. E., Zack, T. I., Beroukhim, R., Garraway, L. A., et al. (2013). ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome research 23, 665-678.
Hanna, M. C., Go, C., Roden, C., Jones, R. T., Pochanard, P., Javed, A. Y., Javed, A., Mondal, C., Palescandolo, E., Van Hummelen, P., et al. (2013). Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PloS one 8, e74950.
Daniels, A. B., Lee, J. E., MacConaill, L. E., Palescandolo, E., Van Hummelen, P., Adams, S. M., DeAngelis, M. M., Hahn, W. C., Gragoudas, E. S., Harbour, J. W., et al. (2012). High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Investigative ophthalmology & visual science 53, 6991-6996.
Nguyen, C. L., Possemato, R., Bauerlein, E. L., Xie, A., Scully, R., and Hahn, W. C. (2012). Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Molecular and cellular biology 32, 3963-3977.
Eck, M. J., and Hahn, W. C. (2012). EGFR in limbo. Cell 149, 735-737.
Bellucci, R., Nguyen, H. N., Martin, A., Heinrichs, S., Schinzel, A. C., Hahn, W. C., and Ritz, J. (2012). Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. The Journal of clinical investigation 122, 2369-2383.
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., Defelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., Macconaill, L. E., Hahn, W. C., et al. (2012). High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery 2, 82-93.
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012). Emerging insights into the molecular and cellular basis of glioblastoma. Genes & development 26, 756-784.
MacConaill, L. E., Van Hummelen, P., Meyerson, M., and Hahn, W. C. (2011). Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer discovery 1, 297-311.
Chin, L., Hahn, W. C., Getz, G., and Meyerson, M. (2011). Making sense of cancer genomic data. Genes & development 25, 534-555.
Boehm, J. S., and Hahn, W. C. (2011). Towards systematic functional characterization of cancer genomes. Nature reviews Genetics 12, 487-498.
Eisenberg, D. M., Harris, E. S., Littlefield, B. A., Cao, S., Craycroft, J. A., Scholten, R., Bayliss, P., Fu, Y., Wang, W., Qiao, Y., et al. (2011). Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 82, 17-33.
Yang, X., Boehm, J. S., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., Green, T. M., et al. (2011). A public genome-scale lentiviral expression library of human ORFs. Nature methods 8, 659-661.
Rosenbluh, J., Nijhawan, D., Chen, Z., Wong, K. K., Masutomi, K., and Hahn, W. C. (2011). RMRP is a non-coding RNA essential for early murine development. PloS one 6, e26270.
Matulonis, U. A., Hirsch, M., Palescandolo, E., Kim, E., Liu, J., van Hummelen, P., MacConaill, L., Drapkin, R., and Hahn, W. C. (2011). High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PloS one 6, e24433.
Schreiber, S. L., Shamji, A. F., Clemons, P. A., Hon, C., Koehler, A. N., Munoz, B., Palmer, M., Stern, A. M., Wagner, B. K., Powers, S., et al. (2010). Towards patient-based cancer therapeutics. Nature biotechnology 28, 904-906.
Singh, A., Ye, M., Bucur, O., Zhu, S., Tanya Santos, M., Rabinovitz, I., Wei, W., Gao, D., Hahn, W. C., and Khosravi-Far, R. (2010). Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Molecular biology of the cell 21, 1140-1152.
Jane-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010). An oncogenic role for ETV1 in melanoma. Cancer research 70, 2075-2084.
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010). Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proceedings of the National Academy of Sciences of the United States of America 107, 11501-11506.
Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., and Ogino, S. (2010). CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International journal of cancer Journal international du cancer 126, 2863-2873.
Garraway, L. A., and Hahn, W. C. (2010). On or off target: mutations, models, and predictions. Science translational medicine 2, 35ps28.
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
Sablina, A. A., Hector, M., Colpaert, N., and Hahn, W. C. (2010). Identification of PP2A complexes and pathways involved in cell transformation. Cancer research 70, 10474-10484.
Irie, H. Y., Shrestha, Y., Selfors, L. M., Frye, F., Iida, N., Wang, Z., Zou, L., Yao, J., Lu, Y., Epstein, C. B., et al. (2010). PTK6 regulates IGF-1-induced anchorage-independent survival. PloS one 5, e11729.
Hahn, C. K., Berchuck, J. E., Ross, K. N., Kakoza, R. M., Clauser, K., Schinzel, A. C., Ross, L., Galinsky, I., Davis, T. N., Silver, S. J., et al. (2009a). Proteomic and genetic approaches identify Syk as an AML target. Cancer cell 16, 281-294.
Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H. W., Boehm, J. S., Ni, M., Geisen, C., Root, D. E., et al. (2009). Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer cell 16, 413-424.
Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
Hutti, J. E., Shen, R. R., Abbott, D. W., Zhou, A. Y., Sprott, K. M., Asara, J. M., Hahn, W. C., and Cantley, L. C. (2009). Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Molecular cell 34, 461-472.
Rosenberg, J. E., and Hahn, W. C. (2009). Bladder cancer: modeling and translation. Genes & development 23, 655-659.
Hahn, W. C., Dunn, I. F., Kim, S. Y., Schinzel, A. C., Firestein, R., Guney, I., and Boehm, J. S. (2009b). Integrative genomic approaches to understanding cancer. Biochimica et biophysica acta 1790, 478-484.
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer cell 16, 21-32.
Migita, T., Ruiz, S., Fornari, A., Fiorentino, M., Priolo, C., Zadra, G., Inazuka, F., Grisanzio, C., Palescandolo, E., Shin, E., et al. (2009). Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. Journal of the National Cancer Institute 101, 519-532.
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009). Profiling critical cancer gene mutations in clinical tumor samples. PloS one 4, e7887.
Possemato, R., Timmons, J. C., Bauerlein, E. L., Wada, N., Baldwin, A., Masutomi, K., and Hahn, W. C. (2008). Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Molecular cancer research : MCR 6, 1582-1593.
Cichowski, K., and Hahn, W. C. (2008). Unexpected pieces to the senescence puzzle. Cell 133, 958-961.
Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J. S., Beroukhim, R., Weir, B. A., et al. (2008). Highly parallel identification of essential genes in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 105, 20380-20385.
Kimmelman, A. C., Hezel, A. F., Aguirre, A. J., Zheng, H., Paik, J. H., Ying, H., Chu, G. C., Zhang, J. X., Sahin, E., Yeo, G., et al. (2008). Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America 105, 19372-19377.
Wiedemeyer, R., Brennan, C., Heffernan, T. P., Xiao, Y., Mahoney, J., Protopopov, A., Zheng, H., Bignell, G., Furnari, F., Cavenee, W. K., et al. (2008). Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer cell 13, 355-364.
Jeong, J. H., Wang, Z., Guimaraes, A. S., Ouyang, X., Figueiredo, J. L., Ding, Z., Jiang, S., Guney, I., Kang, G. H., Shin, E., et al. (2008). BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PloS one 3, e3949.
Firestein, R., Blander, G., Michan, S., Oberdoerffer, P., Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S., de Cabo, R., Fuchs, C., et al. (2008). The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PloS one 3, e2020.
Park, Y., Downing, S. R., Kim, D., Hahn, W. C., Li, C., Kantoff, P. W., and Wei, L. J. (2007). Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics 23, 1451-1458.
Sablina, A. A., Chen, W., Arroyo, J. D., Corral, L., Hector, M., Bulmer, S. E., DeCaprio, J. A., and Hahn, W. C. (2007). The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 129, 969-982.
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., and Sabatini, D. M. (2006). Genome-scale loss-of-function screening with a lentiviral RNAi library. Nature methods 3, 715-719.
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006). Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer cell 10, 321-330.
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298.
Lin, S. S., Bassik, M. C., Suh, H., Nishino, M., Arroyo, J. D., Hahn, W. C., Korsmeyer, S. J., and Roberts, T. M. (2006). PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. The Journal of biological chemistry 281, 23003-23012.
Sjostrom, S. K., Finn, G., Hahn, W. C., Rowitch, D. H., and Kenney, A. M. (2005). The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Developmental cell 9, 327-338.
Dong, C. K., Masutomi, K., and Hahn, W. C. (2005). Telomerase: regulation, function and transformation. Critical reviews in oncology/hematology 54, 85-93.
Hahn, W. C. (2005). Telomere and telomerase dynamics in human cells. Current molecular medicine 5, 227-231.
Boehm, J. S., and Hahn, W. C. (2005). Understanding transformation: progress and gaps. Current opinion in genetics & development 15, 13-17.
Hahn, W. C. (2004a). Cancer: surviving on the edge. Cancer cell 6, 215-222.
Hahn, W. C. (2004b). Experimental models of human cancer. Cell Cycle 3, 604-605.
Hahn, W. C. (2004c). Targeting cancer with telomerase: commentary re Q. Huang et al., a novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 1203-1205.
Yu, E. Y., and Hahn, W. C. (2004). The origin of cancer. Cancer treatment and research 122, 1-22.
Hahn, W. C. (2003). Role of telomeres and telomerase in the pathogenesis of human cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21, 2034-2043.
Masutomi, K., Yu, E. Y., Khurts, S., Ben-Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Murakami, S., DeCaprio, J. A., et al. (2003). Telomerase maintains telomere structure in normal human cells. Cell 114, 241-253.
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G., Jr. (2003). Chemosensitivity linked to p73 function. Cancer cell 3, 403-410.
Hahn, W. C., and Weinberg, R. A. (2002a). Rules for making human tumor cells. The New England journal of medicine 347, 1593-1603.
Hahn, W. C. (2002a). Empty pockets yield more telomere change. Cell Cycle 1, 406-407.
Hahn, W. C., and Weinberg, R. A. (2002b). Modelling the molecular circuitry of cancer. Nature reviews Cancer 2, 331-341.
Hahn, W. C. (2002b). Immortalization and transformation of human cells. Molecules and cells 13, 351-361.
Hahn, W. C. (2002c). Senescence, telomere shortening and telomere maintenance. Cancer biology & therapy 1, 398-400.
Rheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricala, C., and O'Toole, K. M. (2002). A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Molecular and cellular biology 22, 5157-5172.
Hahn, W. C., and Meyerson, M. (2001). Telomerase activation, cellular immortalization and cancer. Annals of medicine 33, 123-129.
Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y., Weinberg, R. A., Louis, D. N., Li, F. P., and Rheinwald, J. G. (2000). Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Molecular and cellular biology 20, 1436-1447.
Vonderheide, R. H., Hahn, W. C., Schultze, J. L., and Nadler, L. M. (1999). The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679.
Hahn, W. C., Menu, E., Bothwell, A. L., Sims, P. J., and Bierer, B. E. (1992). Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science 256, 1805-1807.
Cervia LD, Shibue T, Borah AA, Gaeta B, He L, Leung L, Li N, Moyer SM, Shim BH, Dumont N, Gonzalez A, Bick NR, Kazachkova M, Dempster JM, Krill-Burger JM, Piccioni F, Udeshi ND, Olive ME, Carr SA, Root DE, McFarland JM, Vazquez F, Hahn WC. A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer Discov. 2023 Mar 1;13(3):766-795. doi: 10.1158/2159-8290.CD-22-1230. PMID: 36576405; PMCID: PMC9975667.
Schröfelbauer B, Kimes PK, Hauke P, Reid CE, Shao K, Hill SJ, Irizarry R, Hahn WC. Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2206751120. doi: 10.1073/pnas.2206751120. Epub 2022 Dec 27. PMID: 36574667; PMCID: PMC9910589.
Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC. Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023 Feb 15;83(4):613-625. doi: 10.1158/0008-5472.CAN-22-2245. PMID: 36548402; PMCID: PMC9929516.
So J, Mabe NW, Englinger B, Chow KH, Moyer SM, Yerrum S, Trissal MC, Marques JG, Kwon JJ, Shim B, Pal S, Panditharatna E, Quinn T, Schaefer DA, Jeong D, Mayhew DL, Hwang J, Beroukhim R, Ligon KL, Stegmaier K, Filbin MG, Hahn WC. VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 Oct 10;7(19):e158755. doi: 10.1172/jci.insight.158755. PMID: 36040810; PMCID: PMC9675470.
Pan J, Kwon JJ, Talamas JA, Borah AA, Vazquez F, Boehm JS, Tsherniak A, Zitnik M, McFarland JM, Hahn WC. Sparse dictionary learning recovers pleiotropy from human cell fitness screens. Cell Syst. 2022 Apr 20;13(4):286-303.e10. doi: 10.1016/j.cels.2021.12.005. Epub 2022 Jan 31. PMID: 35085500; PMCID: PMC9035054.
Kim M, Ly SH, Xie Y, Duronio GN, Ford-Roshon D, Hwang JH, Sulahian R, Rennhack JP, So J, Gjoerup O, Talamas JA, Grandclaudon M, Long HW, Doench JG, Sethi NS, Giannakis M, Hahn WC. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Dev Cell. 2022 Jan 24;57(2):212-227.e8. doi: 10.1016/j.devcel.2021.12.006. Epub 2022 Jan 5. PMID: 34990589; PMCID: PMC8827663.
Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, So J, Kregel S, Van Allen EM, Drake JM, Freedman ML, Hahn WC. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies. Elife. 2022 May 12;11:e73223. doi: 10.7554/eLife.73223. PMID: 35550030; PMCID: PMC9135408.
Dai C, Rennhack JP, Arnoff TE, Thaker M, Younger ST, Doench JG, Huang AY, Yang A, Aguirre AJ, Wang B, Mun E, O'Connell JT, Huang Y, Labella K, Talamas JA, Li J, Ilic N, Hwang J, Hong AL, Giacomelli AO, Gjoerup O, Root DE, Hahn WC. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Rep. 2021 Jul 27;36(4):109443. doi: 10.1016/j.celrep.2021.109443. PMID: 34320363; PMCID: PMC8350598.
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, Ly SH, Han C, Dai C, Pakula H, Sheahan A, Piccioni F, Gjoerup O, Loda M, Sowalsky AG, Ellis L, Long H, Root DE, Kelly K, Van Allen EM, Freedman ML, Choudhury AD, Hahn WC (2019). CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 Nov 19;29(8):2355-2370.e6
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ (2019). Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019 Oct 1;29(1):118-134.e8.
Hahn, WC. (2019). A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019 Jun 20;380(25):2475-2477.
Price C, Gill S, Ho ZV, Davidson SM, Merkel E, McFarland JM, Leung L, Tang A, Kost-Alimova M, Tsherniak A, Jonas O, Vazquez F, and Hahn WC. (2019). Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019 May 15;79(10):2564-2579.
Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, Ward A, McSteen B, Labella KM, Keskula P, Tracy A, Connor C, Clinton CM, Church AJ, Crompton BD, Janeway KA, Van Hare B, Sandak D, Gjoerup O, Bandopadhayay P, Clemons PA, Schreiber SL, Root DE, Gokhale PC, Chi SN, Mullen EA, Roberts CW, Kadoch C, Beroukhim R, Ligon KL, Boehm JS, and Hahn WC. (2019). Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 Mar 12;8.
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, and Hahn WC. (2019). MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 Jun;17(6):1294-130.
Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, and Roberts CWM. (2019). MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 May 1;79(9):2404-2414.
Aguirre, A.J., Nowak, J.A., Camarda, N.D., Moffitt, R.A., Ghazani, A.A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L.K., Ragon, D., Welch, M.W., Reilly, E., McCabe, D., Marini, L., Anderka, K., Helvie, K., Oliver, N., Babic, A., Da Silva, A., Nadres, B., Van Seventer, E.E., Shahzade, H.A., St Pierre, J.P., Burke, K.P., Clancy, T., Cleary, J.M., Doyle, L.A., Jajoo, K., McCleary, N.J., Meyerhardt, J.A., Murphy, J.E., Ng, K., Patel, A.K., Perez, K., Rosenthal, M.H., Rubinson, D.A., Ryou, M., Shapiro, G.I., Sicinska, E., Silverman, S.G., Nagy, R.J., Lanman, R.B., Knoerzer, D., Welsch, D.J., Yurgelun, M.B., Fuchs, C.S., Garraway, L.A., Getz, G., Hornick, J.L., Johnson, B.E., Kulke, M.H., Mayer, R.J., Miller, J.W., Shyn, P.B., Tuveson, D.A., Wagle, N., Yeh, J.J., Hahn, W.C., Corcoran, R.B., Carter, S.L., and Wolpin, B.M. (2018). Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer discovery 8, 1096-1111.
Durbin, A.D., Zimmerman, M.W., Dharia, N.V., Abraham, B.J., Iniguez, A.B., Weichert-Leahey, N., He, S., Krill-Burger, J.M., Root, D.E., Vazquez, F., Tsherniak, A., Hahn, W.C., Golub, T.R., Young, R.A., Look, A.T., and Stegmaier, K. (2018). Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature genetics 50, 1240-1246.
Giacomelli, A.O., Yang, X., Lintner, R.E., McFarland, J.M., Duby, M., Kim, J., Howard, T.P., Takeda, D.Y., Ly, S.H., Kim, E., Gannon, H.S., Hurhula, B., Sharpe, T., Goodale, A., Fritchman, B., Steelman, S., Vazquez, F., Tsherniak, A., Aguirre, A.J., Doench, J.G., Piccioni, F., Roberts, C.W.M., Meyerson, M., Getz, G., Johannessen, C.M., Root, D.E., and Hahn, W.C. (2018). Mutational processes shape the landscape of TP53 mutations in human cancer. Nature genetics 50, 1381-1387.
Choudhury, A.D., Werner, L., Francini, E., Wei, X.X., Ha, G., Freeman, S.S., Rhoades, J., Reed, S.C., Gydush, G., Rotem, D., Lo, C., Taplin, M.E., Harshman, L.C., Zhang, Z., O'Connor, E.P., Stover, D.G., Parsons, H.A., Getz, G., Meyerson, M., Love, J.C., Hahn, W.C., and Adalsteinsson, V.A. (2018). Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3.
McFarland, J.M., Ho, Z.V., Kugener, G., Dempster, J.M., Montgomery, P.G., Bryan, J.G., Krill-Burger, J.M., Green, T.M., Vazquez, F., Boehm, J.S., Golub, T.R., Hahn, W.C., Root, D.E., and Tsherniak, A. (2018). Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nature communications 9, 4610.
Lo, J.H., Hao, L., Muzumdar, M.D., Raghavan, S., Kwon, E.J., Pulver, E.M., Hsu, F., Aguirre, A.J., Wolpin, B.M., Fuchs, C.S., Hahn, W.C., Jacks, T., and Bhatia, S.N. (2018). iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Molecular cancer therapeutics 17, 2377-2388.
Pan, J., Meyers, R.M., Michel, B.C., Mashtalir, N., Sizemore, A.E., Wells, J.N., Cassel, S.H., Vazquez, F., Weir, B.A., Hahn, W.C., Marsh, J.A., Tsherniak, A., and Kadoch, C. (2018). Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst 6, 555-568 e557.
Ng, S.Y., Yoshida, N., Christie, A.L., Ghandi, M., Dharia, N.V., Dempster, J., Murakami, M., Shigemori, K., Morrow, S.N., Van Scoyk, A., Cordero, N.A., Stevenson, K.E., Puligandla, M., Haas, B., Lo, C., Meyers, R., Gao, G., Cherniack, A., Louissaint, A., Jr., Nardi, V., Thorner, A.R., Long, H., Qiu, X., Morgan, E.A., Dorfman, D.M., Fiore, D., Jang, J., Epstein, A.L., Dogan, A., Zhang, Y., Horwitz, S.M., Jacobsen, E.D., Santiago, S., Ren, J.G., Guerlavais, V., Annis, D.A., Aivado, M., Saleh, M.N., Mehta, A., Tsherniak, A., Root, D., Vazquez, F., Hahn, W.C., Inghirami, G., Aster, J.C., Weinstock, D.M., and Koch, R. (2018). Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature communications 9, 2024.
Qian, Z.R., Rubinson, D.A., Nowak, J.A., Morales-Oyarvide, V., Dunne, R.F., Kozak, M.M., Welch, M.W., Brais, L.K., Da Silva, A., Li, T., Li, W., Masuda, A., Yang, J., Shi, Y., Gu, M., Masugi, Y., Bui, J., Zellers, C.L., Yuan, C., Babic, A., Khalaf, N., Aguirre, A., Ng, K., Miksad, R.A., Bullock, A.J., Chang, D.T., Tseng, J.F., Clancy, T.E., Linehan, D.C., Findeis-Hosey, J.J., Doyle, L.A., Thorner, A.R., Ducar, M., Wollison, B., Laing, A., Hahn, W.C., Meyerson, M., Fuchs, C.S., Ogino, S., Hornick, J.L., Hezel, A.F., Koong, A.C., and Wolpin, B.M. (2018). Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA oncology 4, e173420.
Li, J., Choi, P.S., Chaffer, C.L., Labella, K., Hwang, J.H., Giacomelli, A.O., Kim, J.W., Ilic, N., Doench, J.G., Ly, S.H., Dai, C., Hagel, K., Hong, A.L., Gjoerup, O., Goel, S., Ge, J.Y., Root, D.E., Zhao, J.J., Brooks, A.N., Weinberg, R.A., and Hahn, W.C. (2018). An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. eLife 7.
Ng, K., Hendifar, A., Starodub, A., Chaves, J., Yang, Y., Koh, B., Barbie, D., Hahn, W.C., and Fuchs, C.S. (2018). Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Investigational new drugs.
Takeda, D.Y., Spisak, S., Seo, J.H., Bell, C., O'Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szallasi, Z., Stillman, D.R., Cejas, P., Qiu, X., Long, H.W., Tisza, V., Nuzzo, P.V., Rohanizadegan, M., Pomerantz, M.M., Hahn, W.C., and Freedman, M.L. (2018). A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell 174, 422-432 e413.
Yurgelun, M.B., Chittenden, A.B., Morales-Oyarvide, V., Rubinson, D.A., Dunne, R.F., Kozak, M.M., Qian, Z.R., Welch, M.W., Brais, L.K., Da Silva, A., Bui, J.L., Yuan, C., Li, T., Li, W., Masuda, A., Gu, M., Bullock, A.J., Chang, D.T., Clancy, T.E., Linehan, D.C., Findeis-Hosey, J.J., Doyle, L.A., Thorner, A.R., Ducar, M.D., Wollison, B.M., Khalaf, N., Perez, K., Syngal, S., Aguirre, A.J., Hahn, W.C., Meyerson, M.L., Fuchs, C.S., Ogino, S., Hornick, J.L., Hezel, A.F., Koong, A.C., Nowak, J.A., and Wolpin, B.M. (2018). Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med.
Viswanathan, S.R., Nogueira, M.F., Buss, C.G., Krill-Burger, J.M., Wawer, M.J., Malolepsza, E., Berger, A.C., Choi, P.S., Shih, J., Taylor, A.M., Tanenbaum, B., Pedamallu, C.S., Cherniack, A.D., Tamayo, P., Strathdee, C.A., Lage, K., Carr, S.A., Schenone, M., Bhatia, S.N., Vazquez, F., Tsherniak, A., Hahn, W.C., and Meyerson, M. (2018). Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nature genetics 50, 937-943.
Chen, L., Alexe, G., Dharia, N.V., Ross, L., Iniguez, A.B., Conway, A.S., Wang, E.J., Veschi, V., Lam, N., Qi, J., Gustafson, W.C., Nasholm, N., Vazquez, F., Weir, B.A., Cowley, G.S., Ali, L.D., Pantel, S., Jiang, G., Harrington, W.F., Lee, Y., Goodale, A., Lubonja, R., Krill-Burger, J.M., Meyers, R.M., Tsherniak, A., Root, D.E., Bradner, J.E., Golub, T.R., Roberts, C.W., Hahn, W.C., Weiss, W.A., Thiele, C.J., and Stegmaier, K. (2018). CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. The Journal of clinical investigation 128, 446-462.
Horn, H., Lawrence, M.S., Chouinard, C.R., Shrestha, Y., Hu, J.X., Worstell, E., Shea, E., Ilic, N., Kim, E., Kamburov, A., Kashani, A., Hahn, W.C., Campbell, J.D., Boehm, J.S., Getz, G., and Lage, K. (2018). NetSig: network-based discovery from cancer genomes. Nature methods 15, 61-66.
Zhang, X., Choi, P.S., Francis, J.M., Gao, G.F., Campbell, J.D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., Tsherniak, A., Taylor, A.M., Zhou, J., Wu, Z., Berger, A.C., Giannakis, M., Hahn, W.C., Cherniack, A.D., and Meyerson, M. (2018). Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer discovery 8, 108-125.
Sandoval, G.J., Pulice, J.L., Pakula, H., Schenone, M., Takeda, D.Y., Pop, M., Boulay, G., Williamson, K.E., McBride, M.J., Pan, J., St Pierre, R., Hartman, E., Garraway, L.A., Carr, S.A., Rivera, M.N., Li, Z., Ronco, L., Hahn, W.C., and Kadoch, C. (2018). Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Molecular cell 71, 554-566 e557.
Aguirre, A.J., and Hahn, W.C. (2018). Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harbor perspectives in medicine 8.
Meyers, R.M., Bryan, J.G., McFarland, J.M., Weir, B.A., Sizemore, A.E., Xu, H., Dharia, N.V., Montgomery, P.G., Cowley, G.S., Pantel, S., Goodale, A., Lee, Y., Ali, L.D., Jiang, G., Lubonja, R., Harrington, W.F., Strickland, M., Wu, T., Hawes, D.C., Zhivich, V.A., Wyatt, M.R., Kalani, Z., Chang, J.J., Okamoto, M., Stegmaier, K., Golub, T.R., Boehm, J.S., Vazquez, F., Root, D.E., Hahn, W.C., and Tsherniak, A. (2017). Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nature genetics.
Gonen, M., Weir, B.A., Cowley, G.S., Vazquez, F., Guan, Y., Jaiswal, A., Karasuyama, M., Uzunangelov, V., Wang, T., Tsherniak, A., Howell, S., Marbach, D., Hoff, B., Norman, T.C., Airola, A., Bivol, A., Bunte, K., Carlin, D., Chopra, S., Deran, A., Ellrott, K., Gopalacharyulu, P., Graim, K., Kaski, S., Khan, S.A., Newton, Y., Ng, S., Pahikkala, T., Paull, E., Sokolov, A., Tang, H., Tang, J., Wennerberg, K., Xie, Y., Zhan, X., Zhu, F., Broad, D.C., Aittokallio, T., Mamitsuka, H., Stuart, J.M., Boehm, J.S., Root, D.E., Xiao, G., Stolovitzky, G., Hahn, W.C., and Margolin, A.A. (2017). A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst 5, 485-497 e483.
Zwang, Y., Jonas, O., Chen, C., Rinne, M.L., Doench, J.G., Piccioni, F., Tan, L., Huang, H.T., Wang, J., Ham, Y.J., et al. (2017). Synergistic interactions with PI3K inhibition that induce apoptosis. Elife 6.
Rosenbluh, J., Xu, H., Harrington, W., Gill, S., Wang, X., Vazquez, F., Root, D.E., Herniate, A., and Hahn, W.C. (2017). Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun 8, 15403.
Sandoval, G.J., and Hahn, W.C. (2017). Going beyond genetics to discover cancer targets. Genome Biol 18, 95.
Hsu, J.H., Hubbell-Engler, B., Adelmant, G., Huang, J., Joyce, C.E., Vazquez, F., Weir, B.A., Montgomery, P., Tsherniak, A., Giacomelli, A.O., et al. (2017). PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res.
Sun, Y., Alberta, J.A., Pilarz, C., Calligaris, D., Chadwick, E.J., Ramkissoon, S.H., Ramkissoon, L.A., Garcia, V.M., Mazzola, E., Goumnerova, L., et al. (2017). A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol 19, 774-785.
Tsherniak, A., Vazquez, F., Montgomery, P.G., Weir, B.A., Kryukov, G., Cowley, G.S., Gill, S., Harrington, W.F., Pantel, S., Krill-Burger, J.M., et al. (2017). Defining a Cancer Dependency Map. Cell 170, 564-576 e516.
Viswanathan, V.S., Ryan, M.J., Dhruv, H.D., Gill, S., Eichhoff, O.M., Seashore-Ludlow, B., Kaffenberger, S.D., Eaton, J.K., Shimada, K., Aguirre, A.J., et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453-457.
Li, H., Mar, B.G., Zhang, H., Puram, R.V., Vazquez, F., Weir, B.A., Hahn, W.C., Ebert, B., and Pellman, D. (2017). The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129, 497-508.
Ni, J., Xie, S., Ramkissoon, S.H., Luu, V., Sun, Y., Bandopadhayay, P., Beroukhim, R., Roberts, T.M., Stiles, C.D., Segal, R.A., et al. (2017). Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19, 22-30.
Paolella, B.R., Gibson, W.J., Urbanski, L.M., Alberta, J.A., Zack, T.I., Bandopadhayay, P., Nichols, C.A., Agarwalla, P.K., Brown, M.S., Lamothe, R., et al. (2017). Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife 6.
Wang, B., Krall, E.B., Aguirre, A.J., Kim, M., Widlund, H.R., Doshi, M.B., Sicinska, E., Sulahian, R., Goodale, A., Cowley, G.S., et al. (2017). ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep 18, 1543-1557.
Choudhury, A.D., Schinzel, A.C., Cotter, M.B., Lis, R.T., Labella, K., Lock, Y.J., Izzo, F., Guney, I., Bowden, M., Li, Y.Y., et al. (2017). Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res 77, 753-765.
Krall, E.B., Wang, B., Munoz, D.M., Ilic, N., Raghavan, S., Niederst, M.J., Yu, K., Ruddy, D.A., Aguirre, A.J., Kim, J.W., et al. (2017). KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife 6.
Day, T.A., Layer, J.V., Cleary, J.P., Guha, S., Stevenson, K.E., Tivey, T., Kim, S., Schinzel, A.C., Izzo, F., Doench, J., et al. (2017). PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun 8, 15110.
Ilic, N., Birsoy, K., Aguirre, A.J., Kory, N., Pacold, M.E., Singh, S., Moody, S.E., DeAngelo, J.D., Spardy, N.A., Freinkman, E., et al. (2017). PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A 114, E3434-E3443.
Rosenbluh, J., Mercer, J., Shrestha, Y., Oliver, R., Tamayo, P., Doench, J.G., Tirosh, I., Piccioni, F., Hartenian, E., Horn, H., et al. (2016). Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers. Cell Syst 3, 302-316 e304.
Sholl, L.M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A.M., Kuo, F.C., Garcia, E.P., Jia, Y., Davineni, P., Abo, R.P., et al. (2016). Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062.
Howard, T.P., Vazquez, F., Tsherniak, A., Hong, A.L., Rinne, M., Aguirre, A.J., Boehm, J.S., and Hahn, W.C. (2016). Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol 81, 237-246.
Kim, J. W., Botvinnik, O. B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M. E., Hammerman, P. S., DiCara, D., Konieczkowski, D. J., et al. (2016a). Characterizing genomic alterations in cancer by complementary functional associations. Nature biotechnology 34, 539-546.
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016). MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214-1218.
Bellmunt, J., Zhou, C. W., Mullane, S. A., Werner, L., Taplin, M. E., Fay, A. P., Choueiri, T. K., Orsola, A., Takeda, D. Y., Hahn, W. C., et al. (2016). Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British journal of cancer 115, 12-19.
Aguirre, A. J., Meyers, R. M., Weir, B. A., Vazquez, F., Zhang, C. Z., Ben-David, U., Cook, A., Ha, G., Harrington, W. F., Doshi, M. B., et al. (2016). Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer discovery.
Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. (2016b). Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer discovery 6, 714-726.
Gannon, H. S., Kaplan, N., Tsherniak, A., Vazquez, F., Weir, B. A., Hahn, W. C., and Meyerson, M. (2016). Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Molecular cancer research : MCR 14, 207-215.
Hong, A. L., Tseng, Y. Y., Cowley, G. S., Jonas, O., Cheah, J. H., Kynnap, B. D., Doshi, M. B., Oh, C., Meyer, S. C., Church, A. J., et al. (2016). Integrated genetic and pharmacologic interrogation of rare cancers. Nature communications 7, 11987.
Luo, L. Y., and Hahn, W. C. (2015). Oncogenic Signaling Adaptor Proteins. Journal of genetics and genomics = Yi chuan xue bao 42, 521-529.
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015). AACR Cancer Progress Report 2015. Clinical cancer research : an official journal of the American Association for Cancer Research 21, S1-128.
Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015). The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nature genetics 47, 1346-1351.
Brastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015). Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer discovery 5, 1164-1177.
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Van Allen, E. M., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015). A functional landscape of resistance to ALK inhibition in lung cancer. Cancer cell 27, 397-408.
White, E. A., Kramer, R. E., Hwang, J. H., Pores Fernando, A. T., Naetar, N., Hahn, W. C., Roberts, T. M., Schaffhausen, B. S., Livingston, D. M., and Howley, P. M. (2015). Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. Journal of virology 89, 2857-2865.
Luo, L. Y., Kim, E., Cheung, H. W., Weir, B. A., Dunn, G. P., Shen, R. R., and Hahn, W. C. (2015). The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular cancer research : MCR 13, 502-509.
Hwang, J. H., Pores Fernando, A. T., Faure, N., Andrabi, S., Adelmant, G., Hahn, W. C., Marto, J. A., Schaffhausen, B. S., and Roberts, T. M. (2015). Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. Journal of virology 89, 6971.
Shen, R. R., Zhou, A. Y., Kim, E., O'Connell, J. T., Hagerstrand, D., Beroukhim, R., and Hahn, W. C. (2015). TRAF2 is an NF-kappaB-activating oncogene in epithelial cancers. Oncogene 34, 209-216.
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L. C., Kung, A. L., et al. (2015). An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America 112, 232-237.
Abo, R. P., Ducar, M., Garcia, E. P., Thorner, A. R., Rojas-Rudilla, V., Lin, L., Sholl, L. M., Hahn, W. C., Meyerson, M., Lindeman, N. I., et al. (2015). BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic acids research 43, e19.
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015). SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nature medicine 21, 1491-1496.
Shankar, G. M., Francis, J. M., Rinne, M. L., Ramkissoon, S. H., Huang, F. W., Venteicher, A. S., Akama-Garren, E. H., Kang, Y. J., Lelic, N., Kim, J. C., et al. (2015). Rapid Intraoperative Molecular Characterization of Glioma. JAMA oncology 1, 662-667.
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., and Hahn, W. C. (2015). PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 34, 2061-2071.
Chen, C. W., Koche, R. P., Sinha, A. U., Deshpande, A. J., Zhu, N., Eng, R., Doench, J. G., Xu, H., Chu, S. H., Qi, J., et al. (2015). DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature medicine 21, 335-343.
Hettmer, S., Schinzel, A. C., Tchessalova, D., Schneider, M., Parker, C. L., Bronson, R. T., Richards, N. G., Hahn, W. C., and Wagers, A. J. (2015). Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. eLife 4.
Huang, F. W., Bielski, C. M., Rinne, M. L., Hahn, W. C., Sellers, W. R., Stegmeier, F., Garraway, L. A., and Kryukov, G. V. (2015). TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4, e176.
Sevenich, L., Bowman, R. L., Mason, S. D., Quail, D. F., Rapaport, F., Elie, B. T., Brogi, E., Brastianos, P. K., Hahn, W. C., Holsinger, L. J., et al. (2014). Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nature cell biology 16, 876-888.
Hwang, J. H., Pores Fernando, A. T., Faure, N., Andrabi, S., Adelmant, G., Hahn, W. C., Marto, J. A., Schaffhausen, B. S., and Roberts, T. M. (2014). Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. Journal of virology 88, 12055-12064.
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., et al. (2014). Prospective enterprise-level molecular genotyping of a cohort of cancer patients. The Journal of molecular diagnostics : JMD 16, 660-672.
Lohr, J. G., Adalsteinsson, V. A., Cibulskis, K., Choudhury, A. D., Rosenberg, M., Cruz-Gordillo, P., Francis, J. M., Zhang, C. Z., Shalek, A. K., Satija, R., et al. (2014). Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature biotechnology 32, 479-484.
Wilson, B. G., Helming, K. C., Wang, X., Kim, Y., Vazquez, F., Jagani, Z., Hahn, W. C., and Roberts, C. W. (2014). Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Molecular and cellular biology 34, 1136-1144.
Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014). ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature medicine 20, 251-254.
Naetar, N., Soundarapandian, V., Litovchick, L., Goguen, K. L., Sablina, A. A., Bowman-Colin, C., Sicinski, P., Hahn, W. C., DeCaprio, J. A., and Livingston, D. M. (2014). PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Molecular cell 54, 932-945.
Lane, A. A., Chapuy, B., Lin, C. Y., Tivey, T., Li, H., Townsend, E. C., van Bodegom, D., Day, T. A., Wu, S. C., Liu, H., et al. (2014). Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature genetics 46, 618-623.
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014). KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184.
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Kramer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124, 13-23.
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014). A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer discovery 4, 816-827.
Chudnovsky, Y., Kim, D., Zheng, S., Whyte, W. A., Bansal, M., Bray, M. A., Gopal, S., Theisen, M. A., Bilodeau, S., Thiru, P., et al. (2014). ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell reports 6, 313-324.
Dunn, G. P., Cheung, H. W., Agarwalla, P. K., Thomas, S., Zektser, Y., Karst, A. M., Boehm, J. S., Weir, B. A., Berlin, A. M., Zou, L., et al. (2014). In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America 111, 1102-1107.
Rosenbluh, J., Wang, X., and Hahn, W. C. (2014). Genomic insights into WNT/beta-catenin signaling. Trends in pharmacological sciences 35, 103-109.
Brastianos, P. K., Taylor-Weiner, A., Manley, P. E., Jones, R. T., Dias-Santagata, D., Thorner, A. R., Lawrence, M. S., Rodriguez, F. J., Bernardo, L. A., Schubert, L., et al. (2014). Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature genetics 46, 161-165.
Sulahian, R., Casey, F., Shen, J., Qian, Z. R., Shin, H., Ogino, S., Weir, B. A., Vazquez, F., Liu, X. S., Hahn, W. C., et al. (2014). An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene 33, 5637-5648.
Giannakis, M., Hodis, E., Jasmine Mu, X., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., Lawrence, M. S., Qian, Z. R., Nishihara, R., et al. (2014). RNF43 is frequently mutated in colorectal and endometrial cancers. Nature genetics 46, 1264-1266.
Riester, M., Werner, L., Bellmunt, J., Selvarajah, S., Guancial, E. A., Weir, B. A., Stack, E. C., Park, R. S., O'Brien, R., Schutz, F. A., et al. (2014). Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 20, 1873-1883.
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014). Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer discovery 4, 452-465.
Hagerstrand, D., Tong, A., Schumacher, S. E., Ilic, N., Shen, R. R., Cheung, H. W., Vazquez, F., Shrestha, Y., Kim, S. Y., Giacomelli, A. O., et al. (2013). Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer discovery 3, 1044-1057.
Etemadmoghadam, D., Au-Yeung, G., Wall, M., Mitchell, C., Kansara, M., Loehrer, E., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013). Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 19, 5960-5971.
Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., MacConaill, L. E., Shoni, M., Wagle, N., Jones, R. T., et al. (2013). Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783.
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., Schumacher, S. E., Zack, T. I., Beroukhim, R., Garraway, L. A., et al. (2013). ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome research 23, 665-678.
Hanna, M. C., Go, C., Roden, C., Jones, R. T., Pochanard, P., Javed, A. Y., Javed, A., Mondal, C., Palescandolo, E., Van Hummelen, P., et al. (2013). Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PloS one 8, e74950.
Daniels, A. B., Lee, J. E., MacConaill, L. E., Palescandolo, E., Van Hummelen, P., Adams, S. M., DeAngelis, M. M., Hahn, W. C., Gragoudas, E. S., Harbour, J. W., et al. (2012). High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Investigative ophthalmology & visual science 53, 6991-6996.
Nguyen, C. L., Possemato, R., Bauerlein, E. L., Xie, A., Scully, R., and Hahn, W. C. (2012). Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Molecular and cellular biology 32, 3963-3977.
Eck, M. J., and Hahn, W. C. (2012). EGFR in limbo. Cell 149, 735-737.
Bellucci, R., Nguyen, H. N., Martin, A., Heinrichs, S., Schinzel, A. C., Hahn, W. C., and Ritz, J. (2012). Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. The Journal of clinical investigation 122, 2369-2383.
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., Defelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., Macconaill, L. E., Hahn, W. C., et al. (2012). High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery 2, 82-93.
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012). Emerging insights into the molecular and cellular basis of glioblastoma. Genes & development 26, 756-784.
MacConaill, L. E., Van Hummelen, P., Meyerson, M., and Hahn, W. C. (2011). Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer discovery 1, 297-311.
Chin, L., Hahn, W. C., Getz, G., and Meyerson, M. (2011). Making sense of cancer genomic data. Genes & development 25, 534-555.
Boehm, J. S., and Hahn, W. C. (2011). Towards systematic functional characterization of cancer genomes. Nature reviews Genetics 12, 487-498.
Eisenberg, D. M., Harris, E. S., Littlefield, B. A., Cao, S., Craycroft, J. A., Scholten, R., Bayliss, P., Fu, Y., Wang, W., Qiao, Y., et al. (2011). Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 82, 17-33.
Yang, X., Boehm, J. S., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., Green, T. M., et al. (2011). A public genome-scale lentiviral expression library of human ORFs. Nature methods 8, 659-661.
Rosenbluh, J., Nijhawan, D., Chen, Z., Wong, K. K., Masutomi, K., and Hahn, W. C. (2011). RMRP is a non-coding RNA essential for early murine development. PloS one 6, e26270.
Matulonis, U. A., Hirsch, M., Palescandolo, E., Kim, E., Liu, J., van Hummelen, P., MacConaill, L., Drapkin, R., and Hahn, W. C. (2011). High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PloS one 6, e24433.
Schreiber, S. L., Shamji, A. F., Clemons, P. A., Hon, C., Koehler, A. N., Munoz, B., Palmer, M., Stern, A. M., Wagner, B. K., Powers, S., et al. (2010). Towards patient-based cancer therapeutics. Nature biotechnology 28, 904-906.
Singh, A., Ye, M., Bucur, O., Zhu, S., Tanya Santos, M., Rabinovitz, I., Wei, W., Gao, D., Hahn, W. C., and Khosravi-Far, R. (2010). Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Molecular biology of the cell 21, 1140-1152.
Jane-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010). An oncogenic role for ETV1 in melanoma. Cancer research 70, 2075-2084.
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010). Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proceedings of the National Academy of Sciences of the United States of America 107, 11501-11506.
Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., and Ogino, S. (2010). CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International journal of cancer Journal international du cancer 126, 2863-2873.
Garraway, L. A., and Hahn, W. C. (2010). On or off target: mutations, models, and predictions. Science translational medicine 2, 35ps28.
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
Sablina, A. A., Hector, M., Colpaert, N., and Hahn, W. C. (2010). Identification of PP2A complexes and pathways involved in cell transformation. Cancer research 70, 10474-10484.
Irie, H. Y., Shrestha, Y., Selfors, L. M., Frye, F., Iida, N., Wang, Z., Zou, L., Yao, J., Lu, Y., Epstein, C. B., et al. (2010). PTK6 regulates IGF-1-induced anchorage-independent survival. PloS one 5, e11729.
Hahn, C. K., Berchuck, J. E., Ross, K. N., Kakoza, R. M., Clauser, K., Schinzel, A. C., Ross, L., Galinsky, I., Davis, T. N., Silver, S. J., et al. (2009a). Proteomic and genetic approaches identify Syk as an AML target. Cancer cell 16, 281-294.
Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H. W., Boehm, J. S., Ni, M., Geisen, C., Root, D. E., et al. (2009). Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer cell 16, 413-424.
Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
Hutti, J. E., Shen, R. R., Abbott, D. W., Zhou, A. Y., Sprott, K. M., Asara, J. M., Hahn, W. C., and Cantley, L. C. (2009). Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Molecular cell 34, 461-472.
Rosenberg, J. E., and Hahn, W. C. (2009). Bladder cancer: modeling and translation. Genes & development 23, 655-659.
Hahn, W. C., Dunn, I. F., Kim, S. Y., Schinzel, A. C., Firestein, R., Guney, I., and Boehm, J. S. (2009b). Integrative genomic approaches to understanding cancer. Biochimica et biophysica acta 1790, 478-484.
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer cell 16, 21-32.
Migita, T., Ruiz, S., Fornari, A., Fiorentino, M., Priolo, C., Zadra, G., Inazuka, F., Grisanzio, C., Palescandolo, E., Shin, E., et al. (2009). Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. Journal of the National Cancer Institute 101, 519-532.
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009). Profiling critical cancer gene mutations in clinical tumor samples. PloS one 4, e7887.
Possemato, R., Timmons, J. C., Bauerlein, E. L., Wada, N., Baldwin, A., Masutomi, K., and Hahn, W. C. (2008). Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Molecular cancer research : MCR 6, 1582-1593.
Cichowski, K., and Hahn, W. C. (2008). Unexpected pieces to the senescence puzzle. Cell 133, 958-961.
Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J. S., Beroukhim, R., Weir, B. A., et al. (2008). Highly parallel identification of essential genes in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 105, 20380-20385.
Kimmelman, A. C., Hezel, A. F., Aguirre, A. J., Zheng, H., Paik, J. H., Ying, H., Chu, G. C., Zhang, J. X., Sahin, E., Yeo, G., et al. (2008). Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America 105, 19372-19377.
Wiedemeyer, R., Brennan, C., Heffernan, T. P., Xiao, Y., Mahoney, J., Protopopov, A., Zheng, H., Bignell, G., Furnari, F., Cavenee, W. K., et al. (2008). Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer cell 13, 355-364.
Jeong, J. H., Wang, Z., Guimaraes, A. S., Ouyang, X., Figueiredo, J. L., Ding, Z., Jiang, S., Guney, I., Kang, G. H., Shin, E., et al. (2008). BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PloS one 3, e3949.
Firestein, R., Blander, G., Michan, S., Oberdoerffer, P., Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S., de Cabo, R., Fuchs, C., et al. (2008). The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PloS one 3, e2020.
Park, Y., Downing, S. R., Kim, D., Hahn, W. C., Li, C., Kantoff, P. W., and Wei, L. J. (2007). Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics 23, 1451-1458.
Sablina, A. A., Chen, W., Arroyo, J. D., Corral, L., Hector, M., Bulmer, S. E., DeCaprio, J. A., and Hahn, W. C. (2007). The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 129, 969-982.
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., and Sabatini, D. M. (2006). Genome-scale loss-of-function screening with a lentiviral RNAi library. Nature methods 3, 715-719.
Hieronymus, H., Lamb, J., Ross, K. N., Peng, X. P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S. M., et al. (2006). Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer cell 10, 321-330.
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298.
Lin, S. S., Bassik, M. C., Suh, H., Nishino, M., Arroyo, J. D., Hahn, W. C., Korsmeyer, S. J., and Roberts, T. M. (2006). PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. The Journal of biological chemistry 281, 23003-23012.
Sjostrom, S. K., Finn, G., Hahn, W. C., Rowitch, D. H., and Kenney, A. M. (2005). The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Developmental cell 9, 327-338.
Dong, C. K., Masutomi, K., and Hahn, W. C. (2005). Telomerase: regulation, function and transformation. Critical reviews in oncology/hematology 54, 85-93.
Hahn, W. C. (2005). Telomere and telomerase dynamics in human cells. Current molecular medicine 5, 227-231.
Boehm, J. S., and Hahn, W. C. (2005). Understanding transformation: progress and gaps. Current opinion in genetics & development 15, 13-17.
Hahn, W. C. (2004a). Cancer: surviving on the edge. Cancer cell 6, 215-222.
Hahn, W. C. (2004b). Experimental models of human cancer. Cell Cycle 3, 604-605.
Hahn, W. C. (2004c). Targeting cancer with telomerase: commentary re Q. Huang et al., a novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 1203-1205.
Yu, E. Y., and Hahn, W. C. (2004). The origin of cancer. Cancer treatment and research 122, 1-22.
Hahn, W. C. (2003). Role of telomeres and telomerase in the pathogenesis of human cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21, 2034-2043.
Masutomi, K., Yu, E. Y., Khurts, S., Ben-Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Murakami, S., DeCaprio, J. A., et al. (2003). Telomerase maintains telomere structure in normal human cells. Cell 114, 241-253.
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G., Jr. (2003). Chemosensitivity linked to p73 function. Cancer cell 3, 403-410.
Hahn, W. C., and Weinberg, R. A. (2002a). Rules for making human tumor cells. The New England journal of medicine 347, 1593-1603.
Hahn, W. C. (2002a). Empty pockets yield more telomere change. Cell Cycle 1, 406-407.
Hahn, W. C., and Weinberg, R. A. (2002b). Modelling the molecular circuitry of cancer. Nature reviews Cancer 2, 331-341.
Hahn, W. C. (2002b). Immortalization and transformation of human cells. Molecules and cells 13, 351-361.
Hahn, W. C. (2002c). Senescence, telomere shortening and telomere maintenance. Cancer biology & therapy 1, 398-400.
Rheinwald, J. G., Hahn, W. C., Ramsey, M. R., Wu, J. Y., Guo, Z., Tsao, H., De Luca, M., Catricala, C., and O'Toole, K. M. (2002). A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Molecular and cellular biology 22, 5157-5172.
Hahn, W. C., and Meyerson, M. (2001). Telomerase activation, cellular immortalization and cancer. Annals of medicine 33, 123-129.
Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y., Weinberg, R. A., Louis, D. N., Li, F. P., and Rheinwald, J. G. (2000). Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Molecular and cellular biology 20, 1436-1447.
Vonderheide, R. H., Hahn, W. C., Schultze, J. L., and Nadler, L. M. (1999). The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679.
Hahn, W. C., Menu, E., Bothwell, A. L., Sims, P. J., and Bierer, B. E. (1992). Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science 256, 1805-1807.